Sign in

Research summary ·

Efficacy of direct-acting antiviral regimens for acute HCV infection: a systematic review and meta-analysis.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This review pooled studies of dual antiviral therapy for new hepatitis C. The therapy had no interferon. It covered acute or recently caught infection. It is seen in clusters among men with HIV and among people who inject drugs. The abstract says early treatment success helps the person and limits spread. The team searched MEDLINE, Scopus and Cochrane until 1 July 2026. The studies reported SVR12, and 1078 treated patients were pooled.

What they found

The pooled SVR12 rate was high. It rose with longer treatment. It was lower at 4 weeks and 6 weeks. It was highest at 8 weeks and 12 weeks. It did not differ by regimen, study design or HIV status. The pooled rate held up in checks.

What it means for patients

The team says the data support early treatment. They favour a course of at least 8 weeks.

Why it is not certain yet

Most data came from single-arm studies with no comparison group. Regimen and treatment length were partly mixed together. The team says randomised trials of treatment length are needed.

Source

Efficacy of direct-acting antiviral regimens for acute HCV infection: a systematic review and meta-analysis.

PubMed · PMID 42850633

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to HIV publications